A coinsurance rate decrease can result in increased adherence to oral antihyperglycemic agents and improved clinical outcomes and cost savings for the healthcare system.
John Kyriopoulos, PhD
Advertisement
Articles by John Kyriopoulos, PhD
Advertisement
Latest Updated Articles
- Abolishing Coinsurance for Oral Antihyperglycemic Agents: Effects on Social Insurance Budgets
Published: March 7th 2011 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Belantamab Mafodotin Combo for Relapsed or Refractory Multiple Myeloma
2
IEHP CEO Weighs in: Who Pays the Price When Millions Lose Medicaid Coverage?
3
Guidelines for Bronchiectasis Highlight Multiple Treatment Methods
4
Ongoing COVID-19 Circulation Linked to Increases in Health-Related Work Absences, Workforce Exits
5
